社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
VivoSim Lab, Inc.(VIVS)
盘后
1.21
0.02
+1.68%
19:58 EDT
1.19
-0.01
-0.83%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
Vivosim Labs, Inc.盘中异动 急速上涨5.41%
市场透视 · 02-26
Vivosim Labs, Inc.盘中异动 急速上涨5.41%
VivoSim Lab, Inc. 通过韩国和中国新分销协议扩大Namkind™人源毒理学服务在亚太地区的可及性
美股速递 · 01-30
VivoSim Lab, Inc. 通过韩国和中国新分销协议扩大Namkind™人源毒理学服务在亚太地区的可及性
Vivosim Labs, Inc.盘中异动 大幅下跌8.35%
市场透视 · 01-09
Vivosim Labs, Inc.盘中异动 大幅下跌8.35%
Vivosim Labs, Inc.盘中异动 早盘股价大涨7.31%
市场透视 · 2025-11-28
Vivosim Labs, Inc.盘中异动 早盘股价大涨7.31%
公司概况
公司名称
VivoSim Lab, Inc.
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.vivosim.ai
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
VivoSim Labs, Inc.成立于2012年1月，从事开发和商业化可以应用在药物发现和开发，进行生物学研究，作为植入受损或退化组织和器官的治疗的人体组织技术平台。VivoSim计划引进到三维人体组织，通过构建三维创作，复制天然人类生物学的潜力。
04-06
超过5%披露
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
04-04
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
04-01
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
04-01
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
03-31
[修订]招股说明书
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
03-31
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
03-31
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
03-28
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
03-28
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
03-27
招股说明书
Form S-1 - General form for registration of securities under the Securities Act of 1933
Form S-1 - General form for registration of securities under the Securities Act of 1933
02-12
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025-12-19
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
2025-11-06
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025-08-29
员工持股计划
Form S-8 - Securities to be offered to employees in employee benefit plans
Form S-8 - Securities to be offered to employees in employee benefit plans
2025-08-14
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
分时
5日
日
周
月
数据加载中...
最高
1.26
今开
1.21
量比
0.27
最低
1.16
昨收
1.20
换手率
0.83%
热议股票
{"pagemeta":{"title":"VivoSim Lab, Inc.(VIVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供VivoSim Lab, Inc.(VIVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"VivoSim Lab, Inc.,VIVS,VivoSim Lab, Inc.股票,VivoSim Lab, Inc.股票老虎,VivoSim Lab, Inc.股票老虎国际,VivoSim Lab, Inc.行情,VivoSim Lab, Inc.股票行情,VivoSim Lab, Inc.股价,VivoSim Lab, Inc.股市,VivoSim Lab, Inc.股票价格,VivoSim Lab, Inc.股票交易,VivoSim Lab, Inc.股票购买,VivoSim Lab, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VivoSim Lab, Inc.(VIVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供VivoSim Lab, Inc.(VIVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"news","symbol":"VIVS","data":{"stockData":{"symbol":"VIVS","market":"US","secType":"STK","nameCN":"VivoSim Lab, Inc.","latestPrice":1.19,"timestamp":1780948800000,"preClose":1.2,"halted":0,"volume":23851,"hourTrading":{"tag":"盘后","latestPrice":1.21,"preClose":1.19,"latestTime":"19:58 EDT","volume":219,"amount":265.4549,"timestamp":1780963138838,"change":0.02,"changeRate":0.016807,"amplitude":0.016807},"delay":0,"changeRate":-0.008333333333333342,"floatShares":2867799,"shares":2894500,"eps":-0.525304,"marketStatus":"未开盘","change":-0.01,"latestTime":"06-08 16:00:00 EDT","open":1.2135,"high":1.26,"low":1.16,"amount":28599.209378000003,"amplitude":0.083333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.525304,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780992000000},"marketStatusCode":0,"adr":0,"listingDate":1373515200000,"exchange":"NASDAQ","adjPreClose":1.2,"preHourTrading":{"tag":"盘前","latestPrice":1.21,"preClose":1.2,"latestTime":"09:06 EDT","volume":540,"amount":685.0899539999999,"timestamp":1780923962231,"change":0.01,"changeRate":0.008333,"amplitude":0.083333},"postHourTrading":{"tag":"盘后","latestPrice":1.21,"preClose":1.19,"latestTime":"19:58 EDT","volume":219,"amount":265.4549,"timestamp":1780963138838,"change":0.02,"changeRate":0.016807,"amplitude":0.016807},"volumeRatio":0.26656},"tweetData":null,"newsData":{"listData":[{"id":"2614049751","title":"Vivosim Labs, Inc.盘中异动 急速上涨5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614049751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614049751?lang=zh_cn&edition=full","pubTime":"2026-02-26 04:11","pubTimestamp":1772050297,"startTime":"0","endTime":"0","summary":"北京时间2026年02月26日04时11分，Vivosim Labs, Inc.股票出现异动，股价快速上涨5.41%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226041137a4c85b45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226041137a4c85b45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VIVS","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134671302","title":"VivoSim Lab, Inc. 通过韩国和中国新分销协议扩大Namkind™人源毒理学服务在亚太地区的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1134671302","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134671302?lang=zh_cn&edition=full","pubTime":"2026-01-30 05:08","pubTimestamp":1769720903,"startTime":"0","endTime":"0","summary":"VivoSim Lab, Inc. 近日宣布，公司已签署新的分销协议，旨在将旗下Namkind™人源毒理学服务更广泛地引入韩国和中国市场。此举标志着该公司在拓展亚太地区业务版图方面迈出了关键一步，旨在满足该区域日益增长的对先进、可靠毒理学测试方案的需求。\n通过此项战略合作，VivoSim Lab, Inc. 将借助当地分销伙伴的网络与专业优势，提升其创新服务的覆盖范围与市场渗透力。Namkind™技术平台以其基于人类生物学的独特测试模型而著称，有望为亚太地区的药物研发、化学品安全评估及相关生命科学领域提供更精准、更具预测性的人体反应数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VIVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602122803","title":"Vivosim Labs, Inc.盘中异动 大幅下跌8.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602122803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602122803?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:55","pubTimestamp":1767894943,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日01时55分，Vivosim Labs, Inc.股票出现异动，股价大幅下挫8.35%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.93%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109015545a4acf44f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109015545a4acf44f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VIVS","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2587075284","title":"Vivosim Labs, Inc.盘中异动 早盘股价大涨7.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2587075284","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587075284?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:33","pubTimestamp":1764340392,"startTime":"0","endTime":"0","summary":"北京时间2025年11月28日22时33分，Vivosim Labs, Inc.股票出现波动，股价大幅上涨7.31%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.19%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128223312a4c0a7f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128223312a4c0a7f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","VIVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"currentPage":1,"bottom":true},"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"20962921","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465926039856-VIVS","pdf_url":"","pub_time":1775448000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","symbol":"VIVS","title":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/000110465926039856/0001104659-26-039856-index.htm","us_notice_code":"Form SCHEDULE 13G","us_title_en":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000110465926039856/xslSCHEDULE_13G_X02/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"SCHEDULE 13G","id":"NTFILE6VNJKASLWuw1GxsT","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2026-04-06 12:00","pubTimestamp":1775448000,"title_zh":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20962065","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526142106-VIVS","pdf_url":"","pub_time":1775246710000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"VIVS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001193125-26-142106-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526142106/vivs-ex99_1.htm","primary":true,"translateUrl":"","linkName":"vivs-ex99_1.htm","type":"EX-99.1","id":"NTFILEfFWw4qGXquDFFEQG","market":"us","size":17735},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526142106/vivs-20260331.htm","primary":false,"translateUrl":"","linkName":"vivs-20260331.htm","type":"8-K","id":"NTFILE7wuvkRvu5JzKhZVV","market":"us","size":74394},{"description":"GRAPHIC","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526142106/img249141941_0.gif","primary":false,"translateUrl":"","linkName":"img249141941_0.gif","type":"GRAPHIC","id":"NTFILEH1RVFCHphfexamk5","market":"us","size":7429}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-04-04 04:05","pubTimestamp":1775246710,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第1.01项：签订重大最终协议；项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21214720","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390026037179-VIVS","pdf_url":"","pub_time":1774977087000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"VIVS","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001213900-26-037179-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026037179/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILE7hKqTWp3QRgZGRGL","market":"us","size":5192}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2026-04-01 01:11","pubTimestamp":1774977087,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21214699","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390026037177-VIVS","pdf_url":"","pub_time":1774976996000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"VIVS","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001213900-26-037177-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026037177/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILEErCgqJiMZ9qDpkkr","market":"us","size":7237}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2026-04-01 01:09","pubTimestamp":1774976996,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20936510","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390026037009-VIVS","pdf_url":"","pub_time":1774929600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]","symbol":"VIVS","title":"Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]","titleType":"[修订]招股说明书","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026037009/0001213900-26-037009-index.htm","us_notice_code":"Form S-1/A","us_title_en":"Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"AMENDMENT NO. 1 TO FORM S-1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026037009/ea0284290-s1a1_vivosim.htm","primary":true,"translateUrl":"","linkName":"ea0284290-s1a1_vivosim.htm","type":"S-1/A","id":"NTFILE5dfYxzJRkCswLAK8","market":"us","size":608632},{"description":"GRAPHIC","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026037009/ea028429001_img1.jpg","primary":false,"translateUrl":"","linkName":"ea028429001_img1.jpg","type":"GRAPHIC","id":"NTFILEA9aTAFLFj3bURJiJ","market":"us","size":8670},{"description":"GRAPHIC","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026037009/ea028429001_img2.jpg","primary":false,"translateUrl":"","linkName":"ea028429001_img2.jpg","type":"GRAPHIC","id":"NTFILE14pRz9fE73kgMQpm","market":"us","size":17274}],"type_name":"招股注册","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"usProspectusesRegistrations","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[修订]招股说明书","pubTime":"2026-03-31 12:00","pubTimestamp":1774929600,"title_zh":"Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21214704","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390026036734-VIVS","pdf_url":"","pub_time":1774922061000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"VIVS","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001213900-26-036734-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026036734/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILECm6w5xX2JUCXBoGb","market":"us","size":5497}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2026-03-31 09:54","pubTimestamp":1774922061,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21214695","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390026036732-VIVS","pdf_url":"","pub_time":1774922029000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"VIVS","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001213900-26-036732-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026036732/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILEHm5gCbSsiVugYP6A","market":"us","size":3963}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2026-03-31 09:53","pubTimestamp":1774922029,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21214727","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390026035818-VIVS","pdf_url":"","pub_time":1774657056000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"VIVS","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001213900-26-035818-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035818/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILEBcx39k1JTtBR5qxr","market":"us","size":5338}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2026-03-28 08:17","pubTimestamp":1774657056,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21214700","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390026035817-VIVS","pdf_url":"","pub_time":1774657041000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"VIVS","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001213900-26-035817-index.html","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035817/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILECzQ9d5KA5jVR9MPf","market":"us","size":6543}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2026-03-28 08:17","pubTimestamp":1774657041,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20910312","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390026035742-VIVS","pdf_url":"","pub_time":1774584000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-1 - General form for registration of securities under the Securities Act of 1933","symbol":"VIVS","title":"Form S-1 - General form for registration of securities under the Securities Act of 1933","titleType":"招股说明书","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/0001213900-26-035742-index.htm","us_notice_code":"Form S-1","us_title_en":"Form S-1 - General form for registration of securities under the Securities Act of 1933","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"REGISTRATION STATEMENT","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea0283777-s1_vivosim.htm","primary":true,"translateUrl":"","linkName":"ea0283777-s1_vivosim.htm","type":"S-1","id":"NTFILESc2mCisUdNYVNoT3","market":"us","size":580520},{"description":"FORM OF PLACEMENT AGENCY AGREEMENT","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex1-1.htm","primary":false,"translateUrl":"","linkName":"ea028377701ex1-1.htm","type":"EX-1.1","id":"NTFILE5uFCxLAEuEiHiZpE","market":"us","size":108872},{"description":"FORM OF PRE-FUNDED WARRANT","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex4-3.htm","primary":false,"translateUrl":"","linkName":"ea028377701ex4-3.htm","type":"EX-4.3","id":"NTFILEFKPR9gUkbRefh781","market":"us","size":86201},{"description":"FORM OF COMMON WARRANT","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex4-4.htm","primary":false,"translateUrl":"","linkName":"ea028377701ex4-4.htm","type":"EX-4.4","id":"NTFILE8ghVcmaZtpDtDLWt","market":"us","size":115365},{"description":"FORM OF PLACEMENT AGENT WARRANT","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex4-5.htm","primary":false,"translateUrl":"","linkName":"ea028377701ex4-5.htm","type":"EX-4.5","id":"NTFILE8DVVjEYuxKtqdVq3","market":"us","size":95883},{"description":"OPINION OF PAUL HASTINGS LLP","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex5-1.htm","primary":false,"translateUrl":"","linkName":"ea028377701ex5-1.htm","type":"EX-5.1","id":"NTFILEBN4623fpYZB8bX5F","market":"us","size":18050},{"description":"FORM OF SECURITIES PURCHASE AGREEMENT","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex10-30.htm","primary":false,"translateUrl":"","linkName":"ea028377701ex10-30.htm","type":"EX-10.30","id":"NTFILE7cDm6JYvxjmUEUsD","market":"us","size":213524},{"description":"CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex23-1.htm","primary":false,"translateUrl":"","linkName":"ea028377701ex23-1.htm","type":"EX-23.1","id":"NTFILE3jBY7KLa1gd9cpTg","market":"us","size":2925},{"description":"FILING FEE TABLE","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex-fee.htm","primary":false,"translateUrl":"","linkName":"ea028377701ex-fee.htm","type":"EX-FILING FEES","id":"NTFILE5etpP2NsM9o657uA","market":"us","size":30623},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701_img1.jpg","primary":false,"translateUrl":"","linkName":"ea028377701_img1.jpg","type":"GRAPHIC","id":"NTFILE8erL3ja7c7ujdQUR","market":"us","size":8670},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701_img2.jpg","primary":false,"translateUrl":"","linkName":"ea028377701_img2.jpg","type":"GRAPHIC","id":"NTFILEDPFJzfHQmuSkPkdW","market":"us","size":17274},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex5-1_img1.jpg","primary":false,"translateUrl":"","linkName":"ea028377701ex5-1_img1.jpg","type":"GRAPHIC","id":"NTFILECMcUugwiyiYRzdwF","market":"us","size":8783},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000121390026035742/ea028377701ex5-1_img2.jpg","primary":false,"translateUrl":"","linkName":"ea028377701ex5-1_img2.jpg","type":"GRAPHIC","id":"NTFILEE9JMXXr6Ld4x8E5G","market":"us","size":16200}],"type_name":"招股注册","type_name_en":"Recruitment Registration","titleTypeEn":"Public Prospectus","us_type":"usProspectusesRegistrations","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"招股说明书","pubTime":"2026-03-27 12:00","pubTimestamp":1774584000,"title_zh":"Form S-1 - General form for registration of securities under the Securities Act of 1933","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20727557","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526046520-VIVS","pdf_url":"","pub_time":1770843926000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"VIVS","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001193125-26-046520-index.html","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526046520/vivs-20251231.htm","primary":true,"translateUrl":"","linkName":"vivs-20251231.htm","type":"10-Q","id":"NTFILEGwoqjq9X4tK5WCpo","market":"us","size":2457614},{"description":"EX-31.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526046520/vivs-ex31_1.htm","primary":false,"translateUrl":"","linkName":"vivs-ex31_1.htm","type":"EX-31.1","id":"NTFILEHBJxsTe1svLky24h","market":"us","size":14112},{"description":"EX-31.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526046520/vivs-ex31_2.htm","primary":false,"translateUrl":"","linkName":"vivs-ex31_2.htm","type":"EX-31.2","id":"NTFILE61Hw5nesduDYHw9K","market":"us","size":14080},{"description":"EX-32.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312526046520/vivs-ex32_1.htm","primary":false,"translateUrl":"","linkName":"vivs-ex32_1.htm","type":"EX-32.1","id":"NTFILE5pKAEqdi7iut9tAh","market":"us","size":11784}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2026-02-12 05:05","pubTimestamp":1770843926,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20549750","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525324794-VIVS","pdf_url":"","pub_time":1766091925000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"VIVS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001193125-25-324794-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 5.07: Submission of Matters to a Vote of Security Holders;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525324794/vivs-20251216.htm","primary":true,"translateUrl":"","linkName":"vivs-20251216.htm","type":"8-K","id":"NTFILE3xhZXJmnKGwNtqk1","market":"us","size":80782}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-12-19 05:05","pubTimestamp":1766091925,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.07: Submission of Matters to a Vote of Security Holders;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目5.07：将事项提交证券持有人表决；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20379157","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525269483-VIVS","pdf_url":"","pub_time":1762405200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"VIVS","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525269483/0001193125-25-269483-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525269483/vivs-20250930.htm","primary":true,"translateUrl":"","linkName":"vivs-20250930.htm","type":"10-Q","id":"NTFILEByh6jFtjERZKTsVb","market":"us","size":2275752},{"description":"EX-31.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525269483/vivs-ex31_1.htm","primary":false,"translateUrl":"","linkName":"vivs-ex31_1.htm","type":"EX-31.1","id":"NTFILEDZguw4KU7gQTMkLi","market":"us","size":14063},{"description":"EX-31.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525269483/vivs-ex31_2.htm","primary":false,"translateUrl":"","linkName":"vivs-ex31_2.htm","type":"EX-31.2","id":"NTFILEA9SKL1YFfLXB6dpm","market":"us","size":14031},{"description":"EX-32.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525269483/vivs-ex32_1.htm","primary":false,"translateUrl":"","linkName":"vivs-ex32_1.htm","type":"EX-32.1","id":"NTFILE7ADbLNuWDU8D5msp","market":"us","size":11688}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2025-11-06 13:00","pubTimestamp":1762405200,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20098409","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312525191220-VIVS","pdf_url":"","pub_time":1756411260000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-8 - Securities to be offered to employees in employee benefit plans","symbol":"VIVS","title":"Form S-8 - Securities to be offered to employees in employee benefit plans","titleType":"员工持股计划","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/0001193125-25-191220-index.html","us_notice_code":"Form S-8","us_title_en":"Form S-8 - Securities to be offered to employees in employee benefit plans","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"S-8","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525191220/d936758ds8.htm","primary":true,"translateUrl":"","linkName":"d936758ds8.htm","type":"S-8","id":"NTFILEEYTd5ehzXaPpv73d","market":"us","size":56823},{"description":"EX-5.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525191220/d936758dex51.htm","primary":false,"translateUrl":"","linkName":"d936758dex51.htm","type":"EX-5.1","id":"NTFILED8wHKKf33ohS8awE","market":"us","size":15308},{"description":"EX-23.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525191220/d936758dex231.htm","primary":false,"translateUrl":"","linkName":"d936758dex231.htm","type":"EX-23.1","id":"NTFILE5qrtfEb9mmKncidb","market":"us","size":1730},{"description":"EX-FILING FEES","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525191220/d936758dexfilingfees.htm","primary":false,"translateUrl":"","linkName":"d936758dexfilingfees.htm","type":"EX-FILING FEES","id":"NTFILEG6ZWUQnaKs1K3BJ2","market":"us","size":12517},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525191220/g936758g0828035834389.jpg","primary":false,"translateUrl":"","linkName":"g936758g0828035834389.jpg","type":"GRAPHIC","id":"NTFILEGcJGQJoHF2mkGBvL","market":"us","size":2494},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525191220/g936758g0828035834569.jpg","primary":false,"translateUrl":"","linkName":"g936758g0828035834569.jpg","type":"GRAPHIC","id":"NTFILE3WKX1koVrc3dy5h1","market":"us","size":3385},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000119312525191220/g936758g0828035834720.jpg","primary":false,"translateUrl":"","linkName":"g936758g0828035834720.jpg","type":"GRAPHIC","id":"NTFILE39FxUjCAmB7ASKXG","market":"us","size":3744}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Employee Stock Ownership","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"员工持股计划","pubTime":"2025-08-29 04:01","pubTimestamp":1756411260,"title_zh":"Form S-8 - Securities to be offered to employees in employee benefit plans","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19986940","market":"us","labels":[],"media":"sec.gov","original_id":"AN95017025108447-VIVS","pdf_url":"","pub_time":1755144000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"VIVS","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/0000950170-25-108447-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-10.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/vivs-ex10_1.htm","primary":true,"translateUrl":"","linkName":"vivs-ex10_1.htm","type":"EX-10.1","id":"NTFILEBVoj1sgJoY9U3gpR","market":"us","size":38211},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/vivs-20250814.htm","primary":false,"translateUrl":"","linkName":"vivs-20250814.htm","type":"8-K","id":"NTFILEyDKRmmZEbV5GhfC7","market":"us","size":58184},{"description":"EX-99.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/vivs-ex99_1.htm","primary":false,"translateUrl":"","linkName":"vivs-ex99_1.htm","type":"EX-99.1","id":"NTFILECWCNNsQoeVGd3SxY","market":"us","size":14104},{"description":"GRAPHIC","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/img62398068_0.jpg","primary":false,"translateUrl":"","linkName":"img62398068_0.jpg","type":"GRAPHIC","id":"NTFILEA28kujnJCxEuVx8Y","market":"us","size":16684}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2025-08-14 12:00","pubTimestamp":1755144000,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第5.02项：董事或某些高级职员的离职；选举董事；若干人员的委任：若干人员的补偿安排；第7.01项：法规FD披露；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.vivosim.ai","stockEarnings":[{"period":"1week","weight":-0.0775},{"period":"1month","weight":-0.1439},{"period":"3month","weight":-0.3737},{"period":"6month","weight":-0.4936},{"period":"1year","weight":-0.3533},{"period":"ytd","weight":-0.3425}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"VivoSim Labs, Inc.成立于2012年1月，从事开发和商业化可以应用在药物发现和开发，进行生物学研究，作为植入受损或退化组织和器官的治疗的人体组织技术平台。VivoSim计划引进到三维人体组织，通过构建三维创作，复制天然人类生物学的潜力。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.001588},{"month":2,"riseRate":0.538462,"avgChangeRate":0.0713},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.135222},{"month":4,"riseRate":0.461538,"avgChangeRate":-0.007295},{"month":5,"riseRate":0.461538,"avgChangeRate":0.044355},{"month":6,"riseRate":0.153846,"avgChangeRate":-0.085784},{"month":7,"riseRate":0.333333,"avgChangeRate":0.012792},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.076461},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.037473},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.055078},{"month":11,"riseRate":0.461538,"avgChangeRate":0.059307},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.024045}],"exchange":"NASDAQ","name":"VivoSim Lab, Inc.","nameEN":"VivoSim Lab, Inc."},"aProfile":null}}}